NCT07152002

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Conditions

• Overweight or Obesity
• Healthy

Interventions

Type	Name	Description
DRUG	LY4064912	Administered SC
DRUG	LY4064912	Administered IV
DRUG	Placebo	Administered SC
DRUG	Placebo	Administered IV

Timeline

• Start date: 2025-08-28
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2025-09-03
• Last updated: 2026-03-03

Locations

3 sites across 2 countries: United States, Singapore

Regulatory

• FDA-regulated drug study